Clinical Trial Update: An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

View source ↗

Summary

This update describes Regeneron's expanded access program for garetosmab in adults with Fibrodysplasia Ossificans Progressiva (FOP), which is currently temporar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Garetosmab (Garetosmab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Fibrodysplasia Ossificans Progressiva (FOP) | Status: TEMPORARILY_NOT_AVAILABLE